Related Experiment Videos
D-Penicillamine--induced pemphigus syndrome
Journal of the American Academy of Dermatology
|March 1, 1982
Summary
D-Penicillamine, a drug used for Wilson's disease and rheumatoid arthritis, can cause serious side effects. This study details a rare case of D-penicillamine-induced pemphigus erythematosus, highlighting potential adverse drug reactions.
Area of Science:
- Pharmacology
- Dermatology
- Autoimmune Diseases
Background:
- D-Penicillamine is a chelating agent with therapeutic applications in Wilson's disease, cystinuria, and lead poisoning.
- It is also utilized in managing rheumatoid arthritis, demonstrating clinical efficacy.
- However, D-penicillamine is associated with a spectrum of adverse effects, including dermatological and systemic reactions.
Observation:
- A patient developed pemphigus erythematosus, a rare autoimmune blistering condition.
- This condition emerged following treatment with D-penicillamine.
- The presentation was characterized by specific clinical and immunological features consistent with drug-induced pemphigus.
Findings:
- The case presented is identified as D-penicillamine-induced pemphigus erythematosus.
- A review of existing literature reveals prior reports of D-penicillamine inducing pemphigus eruptions since 1969.
- This reinforces the association between D-penicillamine and the induction of pemphigus.
Implications:
- Clinicians should be vigilant for pemphigus erythematosus in patients treated with D-penicillamine.
- Early recognition and discontinuation of the drug are crucial for managing this adverse effect.
- Understanding drug-induced autoimmunity is essential for patient safety and therapeutic management.